Claims for Patent: 11,998,555

« Back to Dashboard

Summary for Patent: 11,998,555

Title:	Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
Abstract:	Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.
Inventor(s):	Alfredo Grossi, Britt Kostraba, Olatokumbo O. Luca Ogunleye, Shannon Terry, Franciscus KOPPENHAGEN
Assignee:	ScPharmaceuticals Inc
Application Number:	US17/426,765
Patent Claims:	1. A liquid pharmaceutical formulation comprising: (i) furosemide, or a pharmaceutically acceptable salt thereof; (ii) benzyl alcohol, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.1% (w/w) to about 10% (w/w); and (iii) a pharmaceutically acceptable buffer comprising tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of tromethamine is from about 25 mM to about 100 mM, wherein the concentration of furosemide in the liquid pharmaceutical formulation is greater than about 40 mg/mL and the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5. 2. The liquid pharmaceutical formulation of claim 1, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.5% (w/w) to about 5% (w/w). 3. A liquid pharmaceutical formulation, comprising: (i) furosemide, or a pharmaceutically acceptable salt thereof; (ii) from about 0.1% (w/w) to about 10% (w/w) benzyl alcohol; and (iii) from about 25 mM to about 100 mM tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide in the liquid pharmaceutical formulation is from about 40 mg/mL to about 250 mg/mL. 4. The liquid pharmaceutical formulation of claim 3, wherein the amount of benzyl alcohol in the liquid pharmaceutical formulation is from about 0.5% (w/w) to about 5% (w/w). 5. The liquid pharmaceutical formulation of claim 3, wherein the pH of the liquid pharmaceutical formulation is from about 6.5 to about 8.5. 6. The liquid pharmaceutical formulation of claim 3, wherein the pH of the liquid pharmaceutical formulation is from about 7.0 to about 8.0. 7. A unit liquid pharmaceutical formulation comprising: (i) from about 10 mg to about 200 mg furosemide, or a pharmaceutically acceptable salt thereof; (ii) from about 0.1% (w/w) to about 10% (w/w) benzyl alcohol; and (iii) from about 25 mM to about 100 mM tromethamine or a pharmaceutically acceptable salt thereof, wherein the concentration of furosemide in the unit liquid pharmaceutical formulation is from about 40 mg/mL to about 200 mg/mL and the pH of the unit liquid pharmaceutical formulation is from about 6.5 to about 8.5. 8. The unit liquid pharmaceutical formulation of claim 7, wherein the amount of benzyl alcohol in the unit liquid pharmaceutical formulation is from about 0.5% (w/w) to about 5% (w/w). 9. The liquid pharmaceutical formulation of claim 1, further comprising one of more of water; a pH adjuster; and an osmolarity adjuster. 10. The liquid pharmaceutical formulation of claim 9, wherein the pH adjuster is selected from the group consisting of potassium hydroxide, sodium hydroxide, hydrochloric acid, and combinations thereof; and the osmolarity adjuster is selected from the group consisting of sodium chloride, potassium chloride, and combinations thereof. 11. A method of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof, the method comprising administering to the patient the liquid pharmaceutical formulation of claim 1. 12. The method of claim 11, wherein the liquid pharmaceutical formulation is administered to the patient by subcutaneous injection or subcutaneous infusion. 13. The method of claim 12, wherein the liquid pharmaceutical formulation is administered to the patient by subcutaneous infusion using an on-body, subcutaneous delivery system. 14. A kit for the treatment of congestion, edema, fluid overload, or hypertension comprising the unit liquid pharmaceutical formulation of claim 7. 15. The kit of claim 14, comprising one, two, three or more units of the unit liquid pharmaceutical formulation. 16. The liquid pharmaceutical formulation of claim 3, further comprising one of more of water; a pH adjuster; and an osmolarity adjuster. 17. The liquid pharmaceutical formulation or the unit liquid pharmaceutical formulation of claim 16, wherein the pH adjuster is selected from the group consisting of potassium hydroxide, sodium hydroxide, hydrochloric acid, and combinations thereof; and the osmolarity adjuster is selected from the group consisting of sodium chloride, potassium chloride, and combinations thereof. 18. The unit liquid pharmaceutical formulation of claim 7, further comprising one of more of water; a pH adjuster; and an osmolarity adjuster. 19. The unit liquid pharmaceutical formulation of claim 18, wherein the pH adjuster is selected from the group consisting of potassium hydroxide, sodium hydroxide, hydrochloric acid, and combinations thereof; and the osmolarity adjuster is selected from the group consisting of sodium chloride, potassium chloride, and combinations thereof. 20. The unit liquid pharmaceutical formulation of claim 7, wherein the pH of the unit liquid pharmaceutical formulation is from about 7.0 to about 8.0.